Aastrom Biosciences Inc Stock price Nasdaq
Equities
US00253U3059
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- USD | 0.00% |
Mar. 15 | Vericel Insider Sold Shares Worth $1,552,075, According to a Recent SEC Filing | MT |
Mar. 13 | Vericel Insider Sold Shares Worth $352,047, According to a Recent SEC Filing | MT |
Financials (USD)
Sales 2024 * | 239M | Sales 2025 * | 299M | Capitalization | 2.53B |
---|---|---|---|---|---|
Net income 2024 * | 4M | Net income 2025 * | 25M | EV / Sales 2024 * | 10.6 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 8.45 x |
P/E ratio 2024 * |
654
x | P/E ratio 2025 * |
108
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.17% |
Latest transcript on Aastrom Biosciences Inc
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 60 | 13-02-28 | |
Joseph Mara
DFI | Director of Finance/CFO | 49 | 21-01-24 |
Michael Halpin
COO | Chief Operating Officer | 62 | 17-04-09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Wotton
BRD | Director/Board Member | 63 | 15-01-05 |
Kevin McLaughlin
BRD | Director/Board Member | 67 | 15-01-05 |
Robert Zerbe
CHM | Chairman | 73 | 06-01-15 |
1st Jan change | Capi. | |
---|---|---|
+0.44% | 90.27B | |
+10.00% | 44.05B | |
-16.40% | 31.45B | |
+44.23% | 23.35B | |
-8.10% | 16.72B | |
-25.64% | 15.09B | |
-9.03% | 12.82B | |
-9.37% | 11.95B | |
+98.58% | 7.67B |
- Stock
- Equities
- Stock Vericel Corporation
- Stock Aastrom Biosciences Inc - Nasdaq